• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, April 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Potential new surgical options for women with multiple ipsilateral breast cancer

Bioengineer by Bioengineer
July 12, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Mark Washburn

Lebanon, NH – A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy. Out of 198 eligible women in the trial, 184 (92.9%) successfully completed breast-conserving surgery, 134 of those with a single operation. These findings have just been published online first in Annals of Surgical Oncology.

Advancements in breast cancer care allow for improved control over local disease in patients undergoing breast-conserving surgery. Other advancements such as more sensitive imaging techniques also now result in higher detection rates, which opens up new questions for both breast cancer patients and clinicians about how to best manage disease.

The question was approached in a new collaborative, multi-institutional study conducted by the Alliance for Clinical Trials in Oncology and led by Kari Rosenkranz, MD, a surgical oncologist and medical director of the Comprehensive Breast Program at Dartmouth's Norris Cotton Cancer Center and associate professor of surgery at Geisel School of Medicine at Dartmouth. "Our study is the first prospective study to assess the feasibility and safety of breast conservation in women with two or three malignant lesions in a single breast," says Rosenkranz. The endpoints measured include local recurrence at 5 years, as well as rates of surgical conversion to mastectomy or second surgeries due to positive margins (malignant tissue around the disease site remaining after surgery).

Based on retrospective studies from previous decades, mastectomy has been, and is still, the predominant surgical treatment option for women with multiple ipsilateral breast cancer. These studies, from an era prior to modern technology and multimodality breast cancer care, showed higher rates of local recurrence, ranging from 23-40%, for women in this category who underwent breast-conserving therapy.

This new study finds that for the majority of women enrolled in the trial, 92.9%, breast-conserving surgery is technically feasible. "Results show an acceptably low rate of conversion to mastectomy, and most women successfully achieving breast conservation with negative margins in a single operation," says Rosenkranz. "These data may inform conversations between patients and surgeons regarding management of multiple ipsilateral breast cancer."

Next steps include assessment of the primary study end point, which is local recurrence rates, as well as additional secondary endpoints including breast cosmetic improvement and appropriateness of radiation fields in this patient population.

###

Co-authors are Karla Ballman, PhD, of Alliance Statistics and Data Center, Weill Medical College of Cornell University; Linda McCall, MS, of Alliance Statistics and Data Center, Duke University; Charlotte Kubicky, MD, of Oregon Health and Science University; Laurie Cuttino, MD, of Virginia Commonwealth University Health System; Huong Le-Petross, MD, and Kelly K. Hunt, MD, of The University of Texas MD Anderson Cancer Center; Armando Giuliano, MD, of Cedars-Sinai Medical Center; Kimberly J. Van Zee, MD, of Memorial Sloan Kettering Cancer Center; Bruce Haffty, MD, of Rutgers Cancer Institute of New Jersey; and Judy C. Boughey, MD, of Mayo Clinic.

Media Contact

Jaime Peyton, Director of Communications
[email protected]
603-653-3615

http://www.dhmc.org/webpage.cfm?org_id=796

Original Source

https://link.springer.com/article/10.1245/s10434-018-6583-6?wt_mc=Internal.Event.1.SEM.ArticleAuthorOnlineFirst http://dx.doi.org/10.1245/s10434-018-6583-6

Share14Tweet7Share2ShareShareShare1

Related Posts

REV-ERBα/BNIP3 Axis Reduces Pulmonary Hypertension via Mitophagy

April 2, 2026

Gomesin Cytotoxicity Driven by Glycosphingolipids, Cholesterol

April 2, 2026

Gut Microbiome’s Role in Gastric Cancer Therapy

April 2, 2026

Spike in Kava-Related Inquiries Reported by Poison Control Centers

April 2, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1007 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

REV-ERBα/BNIP3 Axis Reduces Pulmonary Hypertension via Mitophagy

Gomesin Cytotoxicity Driven by Glycosphingolipids, Cholesterol

Gut Microbiome’s Role in Gastric Cancer Therapy

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.